Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2

  title={Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2},
  author={Baomin Tian and Wah Yau Wong and Marni D. Uger and Pawel Wisniewski and Heman Chao},
  journal={Frontiers in Immunology},
Angiogenesis is the process of new blood vessel formation and is essential for a tumor to grow beyond a certain size. Tumors secrete the pro-angiogenic factor vascular endothelial growth factor, which acts upon local endothelial cells by binding to vascular endothelial growth factor receptors (VEGFRs). In this study, we describe the development and characterization of V21-DOS47, an immunoconjugate that targets VEGFR2. V21-DOS47 is composed of a camelid single domain anti-VEGFR2 antibody (V21… 
13 Citations

Figures from this paper

Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases
The characteristic properties of single-domain antibodies compared to traditional antibodies are introduced and recent advances in the development of sdAbs are presented, including their use for the delivery of biologics across the blood–brain and blood–cerebrospinal fluid barriers, treatment of neurodegenerative diseases and molecular imaging of brain targets.
Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment
Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications and it can be expected that more and more multimeric nanobody molecules will undergo late clinical trials in the next future.
Anticancer Activity of Urease Mimetic Cobalt (III) Complexes on A549-Lung Cancer Cells: Targeting the Acidic Microenvironment
The study confirms the urease mimicking anticancer activity of cobalt (III) complexes by neutralizing the tumour microenvironment.
The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance
The present article matches the molecular, histology and microenvironment features of pancreatic cancer to understand the molecular basis of this kind of tumor, and how their microenvironment may affect treatment response, and provides for each subtype a potential description of the tumor microenvironment that may influence treatment response.
Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer
This study suggests that tumour acidity contributes to prostate carcinogenesis by altering the state of macrophage activation by turning off acid-induced cellular responses, and shows that acid-resistant macrophages can limit tumour progression.
Direct capture and selective elution of a secreted polyglutamate‐tagged nanobody using bare magnetic nanoparticles
The secretion and direct capture of proteins from the extracellular medium is a promising approach for purification, thus enabling integrated bioprocesses.


Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer.
A novel immunoconjugate (L-DOS47) was developed and characterized as a therapeutic agent for tumors expressing CEACAM6 and is being investigated as a potential therapeutic agent in human phase I clinical studies for nonsmall cell lung cancer.
From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara
Napoleone Ferrara's work is revolutionizing quality of life for many of the estimated 1.2 million individuals in the US who have wet AMD and the design in a rational fashion in 1997 of a humanized anti-VEGF monoclonal antibody (Avastin), now in clinical trials as a treatment for several solid tumors and outside of cancer.
Efficient tumor targeting by single‐domain antibody fragments of camels
This study demonstrates the successful and specific in vivo targeting of tumors by camel single‐domain fragments, which may open perspectives for their future use as tumor‐targeting vehicle, due to their small size, soluble behaviour and because they are non‐immunogenic and interact with epitopes that are less antigenic for conventional antibodies.
Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers.
Alkalinization of extracellular pH by urease and urea was found to enhance the antitumor efficacy of doxorubicin and vinblastine significantly and when combined with weak-base anticancer drugs, Urease provided indirect antitumors effects via pH augmentation.
Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies
Evidence is provided that dromedary heavy‐chain antibodies, in vivo‐matured in the absence of light chains, are a unique source of inhibitory antibodies that appear to be potent enzyme inhibitors when tested in chromogenic assays.
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature.
Concomitant over‐expression of vascular endothelial growth factor and its receptors in pancreatic cancer
The expression of VEGF and its receptors flk‐1/KDR and flt‐1 in the normal human pancreas and in human pancreatic cancer tissues and cell lines is characterized to suggest that in some instances V EGF may directly promote pancreatic cancers growth via the MAPK pathway.
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
Despite the positive results seen in REVEL, the exact role of ramucirumab in the treatment paradigm of lung cancer remains to be seen given the modest survival benefit of 1.4 months and the lack of predictive biomarkers at this time.